These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

607 related articles for article (PubMed ID: 26364613)

  • 41. Targeting LINC00152 activates cAMP/Ca
    Saatci O; Alam R; Huynh-Dam KT; Isik A; Uner M; Belder N; Ersan PG; Tokat UM; Ulukan B; Cetin M; Calisir K; Gedik ME; Bal H; Sener Sahin O; Riazalhosseini Y; Thieffry D; Gautheret D; Ogretmen B; Aksoy S; Uner A; Akyol A; Sahin O
    Cell Death Dis; 2024 Jun; 15(6):418. PubMed ID: 38879508
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tamoxifen stimulates the growth of cyclin D1-overexpressing breast cancer cells by promoting the activation of signal transducer and activator of transcription 3.
    Ishii Y; Waxman S; Germain D
    Cancer Res; 2008 Feb; 68(3):852-60. PubMed ID: 18245487
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mechanisms of tamoxifen resistance.
    Ring A; Dowsett M
    Endocr Relat Cancer; 2004 Dec; 11(4):643-58. PubMed ID: 15613444
    [TBL] [Abstract][Full Text] [Related]  

  • 44. BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo.
    Cheng S; Castillo V; Welty M; Alvarado M; Eliaz I; Temm CJ; Sandusky GE; Sliva D
    BMC Complement Altern Med; 2017 Feb; 17(1):115. PubMed ID: 28209156
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.
    deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M
    Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Circulating long non-coding HOX transcript antisense intergenic ribonucleic acid in plasma as a potential biomarker for diagnosis of breast cancer.
    Zhang Y; Zhang K; Luo Z; Liu L; Wu L; Liu J
    Thorac Cancer; 2016 Nov; 7(6):627-632. PubMed ID: 27755794
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Suppression of long non-coding RNA CCAT2 improves tamoxifen-resistant breast cancer cells' response to tamoxifen].
    Cai Y; He J; Zhang D
    Mol Biol (Mosk); 2016; 50(5):821-827. PubMed ID: 27830684
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Restoration of tamoxifen sensitivity in estrogen receptor-negative breast cancer cells: tamoxifen-bound reactivated ER recruits distinctive corepressor complexes.
    Sharma D; Saxena NK; Davidson NE; Vertino PM
    Cancer Res; 2006 Jun; 66(12):6370-8. PubMed ID: 16778215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased expression of estrogen receptor beta mRNA in tamoxifen-resistant breast cancer patients.
    Speirs V; Malone C; Walton DS; Kerin MJ; Atkin SL
    Cancer Res; 1999 Nov; 59(21):5421-4. PubMed ID: 10554009
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HOTAIR: An Oncogenic Long Non-Coding RNA in Human Cancer.
    Tang Q; Hann SS
    Cell Physiol Biochem; 2018; 47(3):893-913. PubMed ID: 29843138
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
    Morrissey JJ; Raney S
    Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance.
    Malorni L; Giuliano M; Migliaccio I; Wang T; Creighton CJ; Lupien M; Fu X; Hilsenbeck SG; Healy N; De Angelis C; Mazumdar A; Trivedi MV; Massarweh S; Gutierrez C; De Placido S; Jeselsohn R; Brown M; Brown PH; Osborne CK; Schiff R
    Mol Cancer Res; 2016 May; 14(5):470-81. PubMed ID: 26965145
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells.
    Yang Z; Barnes CJ; Kumar R
    Clin Cancer Res; 2004 Jun; 10(11):3621-8. PubMed ID: 15173068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Artemin is estrogen regulated and mediates antiestrogen resistance in mammary carcinoma.
    Kang J; Qian PX; Pandey V; Perry JK; Miller LD; Liu ET; Zhu T; Liu DX; Lobie PE
    Oncogene; 2010 Jun; 29(22):3228-40. PubMed ID: 20305694
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Kinase-specific phosphorylation of the estrogen receptor changes receptor interactions with ligand, deoxyribonucleic acid, and coregulators associated with alterations in estrogen and tamoxifen activity.
    Likhite VS; Stossi F; Kim K; Katzenellenbogen BS; Katzenellenbogen JA
    Mol Endocrinol; 2006 Dec; 20(12):3120-32. PubMed ID: 16945990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
    McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
    Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Elevated GCN5 expression confers tamoxifen resistance by upregulating AIB1 expression in ER-positive breast cancer.
    Oh JH; Lee JY; Kim KH; Kim CY; Jeong DS; Cho Y; Nam KT; Kim MH
    Cancer Lett; 2020 Dec; 495():145-155. PubMed ID: 32987137
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The lncRNA landscape of breast cancer reveals a role for DSCAM-AS1 in breast cancer progression.
    Niknafs YS; Han S; Ma T; Speers C; Zhang C; Wilder-Romans K; Iyer MK; Pitchiaya S; Malik R; Hosono Y; Prensner JR; Poliakov A; Singhal U; Xiao L; Kregel S; Siebenaler RF; Zhao SG; Uhl M; Gawronski A; Hayes DF; Pierce LJ; Cao X; Collins C; Backofen R; Sahinalp CS; Rae JM; Chinnaiyan AM; Feng FY
    Nat Commun; 2016 Sep; 7():12791. PubMed ID: 27666543
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HBXIP is a novel regulator of the unfolded protein response that sustains tamoxifen resistance in ER+ breast cancer.
    Zhang S; Wang R; Wang X; Guo X; Du Y; Guo X; Zong X; Zhu C; Zhou X
    J Biol Chem; 2022 Mar; 298(3):101644. PubMed ID: 35093383
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers.
    Mohseni M; Cidado J; Croessmann S; Cravero K; Cimino-Mathews A; Wong HY; Scharpf R; Zabransky DJ; Abukhdeir AM; Garay JP; Wang GM; Beaver JA; Cochran RL; Blair BG; Rosen DM; Erlanger B; Argani P; Hurley PJ; Lauring J; Park BH
    Proc Natl Acad Sci U S A; 2014 Dec; 111(49):17606-11. PubMed ID: 25422431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.